Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood.
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
Theoretische concentratiecurve bij een halfwaardetijd van 0.4 h. Puur farmacokinetisch model — geen doseringsaanbeveling.
Open in PK tool →Peptiden komen als droog poeder. Eenmaal opgelost in een vloeistof (reconstitutie) beantwoordt deze calculator één enkele vraag: hoeveel stof zit er daarna in één milliliter oplossing?
Alleen wetenschap, geen verkoop. Op elk moment afmelden.
We store your email only for the newsletter. Unsubscribe anytime. Privacy